Biological inadequacies in the 2D cultures and lack of cost effectiveness and slow speed in animal models is a major barrier for evaluation of a broad array of combination treatments. Our laboratory is developing heterocellular 3D models as a viable, rapid platform for testing a larger variety of combination strategies, combined with biomarker monitoring by high throughput imaging and acoustic cell printing. This work provides a platform for evaluating therapies for a broad array of cancers. In addition to 3D in vitro models, we have also developed in vivo models for various cancers, including orthotropic pancreatic and disseminated ovarian cancer models.